180 Life Sciences Net debt/EBITDA
Quel est le Net debt/EBITDA de 180 Life Sciences?
Le Net debt/EBITDA de 180 Life Sciences Corp. est 0.23
Quelle est la définition de Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA des entreprises dans Health Care secteur sur NASDAQ par rapport à 180 Life Sciences
Que fait 180 Life Sciences?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Entreprises avec net debt/ebitda similaire à 180 Life Sciences
- Kapston Facilities Management a Net debt/EBITDA de 0.22
- EOG Resources a Net debt/EBITDA de 0.23
- Aptorum a Net debt/EBITDA de 0.23
- Agenus Inc a Net debt/EBITDA de 0.23
- Biolife Solutions Inc a Net debt/EBITDA de 0.23
- Infinity Logistics a Net debt/EBITDA de 0.23
- 180 Life Sciences a Net debt/EBITDA de 0.23
- First Bancorp a Net debt/EBITDA de 0.24
- Flexiroam a Net debt/EBITDA de 0.24
- Trxade Health Inc a Net debt/EBITDA de 0.24
- Mkango Resources a Net debt/EBITDA de 0.24
- Ausmon Resources a Net debt/EBITDA de 0.24
- Elmo Software a Net debt/EBITDA de 0.24